Armed with a recent authorization from the FDA, eye specialists are offering light therapy to patients with non-exudative (dry) age-related macular degeneration (AMD), aiming to stop or even reverse ...

Age-Related Macular Degeneration (AMD) is the biggest cause of sight loss in the UK, affecting around 700,000 people. As ...

A laser treatment for this common eye disease will start clinical trials in Finland next spring ––researchers hope it could be available to sufferers in as little as three years Around a third of ...

PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology ...

Please provide your email address to receive an email when new articles are posted on . GLP-1 drugs were linked to significantly lower risk for age-related cataracts. They were also tied to reduced ...

– In AVONELLE-X, the largest long-term extension trial in wet AMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end – – Over 60% ...

Please provide your email address to receive an email when new articles are posted on . Central retinal thickness and macular volume increased at 2 months postop but returned to preop levels at 6 ...

There is strong interest across many stakeholders to increase progress around developing treatments for dry age-related macular degeneration (AMD). Advancements in drug discovery and development in ...